Notable Labs Notable Labs
  • ABOUT
    • ABOUT US
    • OUR MISSION
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • PLATFORM & PIPELINE
    • PREDICTIVE PRECISION MEDICINE PLATFORM
    • VOLASERTIB & FOSCICLOPIROX
  • NEWS
    • All News
    • Investor Events and Presentations
    • Press Releases
    • Scientific Presentations & Publications
    • Content Search
  • Investors
    • Investor Overview
    • SEC Filings
    • Financials
    • Governance
    • IR Contacts
    • Partnership
    • Stock Information
  • Careers
  1. You are here:  
  2. Publications
  3. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study
Details
Category: Publications
08.Oct

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study

A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling.

External Link:

https://clincancerres.aacrjournals.org/content/clincanres/early/2019/11/12/1078-0432.CCR-19-1800.full.pdf

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US

  • PRIVACY POLICY
  • TERM OF USE
  • COOKIE STATEMENT
  • INVESTOR OVERVIEW
  • CAREERS
  • CONTACT US

Copyright © 2023 Notable

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Accept Decline
Cookie Statement